Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors.

IF 11.4 1区 医学 Q1 ONCOLOGY
Yan Li, Zimu Zhang, Juanjuan Yu, Hongli Yin, Xinran Chu, Haibo Cao, Yanfang Tao, Yongping Zhang, Zhiheng Li, Shuiyan Wu, Yizhou Hu, Frank Zhu, Jizhao Gao, Xiaodong Wang, Bi Zhou, Wanyan Jiao, Yumeng Wu, Yang Yang, Yanling Chen, Ran Zhuo, Ying Yang, Fenli Zhang, Lei Shi, Yixin Hu, Jian Pan, Shaoyan Hu
{"title":"Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors.","authors":"Yan Li, Zimu Zhang, Juanjuan Yu, Hongli Yin, Xinran Chu, Haibo Cao, Yanfang Tao, Yongping Zhang, Zhiheng Li, Shuiyan Wu, Yizhou Hu, Frank Zhu, Jizhao Gao, Xiaodong Wang, Bi Zhou, Wanyan Jiao, Yumeng Wu, Yang Yang, Yanling Chen, Ran Zhuo, Ying Yang, Fenli Zhang, Lei Shi, Yixin Hu, Jian Pan, Shaoyan Hu","doi":"10.1186/s13046-024-03199-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite significant progress in the prognosis of pediatric T-cell acute lymphoblastic leukemia (T-ALL) in recent decades, a notable portion of children still confronts challenges such as treatment resistance and recurrence, leading to limited options and a poor prognosis. LIM domain-binding protein 1 (LDB1) has been confirmed to exert a crucial role in various physiological and pathological processes. In our research, we aim to elucidate the underlying function and mechanisms of LDB1 within the background of T-ALL.</p><p><strong>Methods: </strong>Employing short hairpin RNA (shRNA) techniques, we delineated the functional impact of LDB1 in T-ALL cell lines. Through the application of RNA-Seq, CUT&Tag, and immunoprecipitation assays, we scrutinized master transcription factors cooperating with LDB1 and identified downstream targets under LDB1 regulation.</p><p><strong>Results: </strong>LDB1 emerges as a critical transcription factor co-activator in cell lines derived from T-ALL. It primarily collaborates with master transcription factors (ERG, ETV6, IRF1) to cooperatively regulate the transcription of downstream target genes. Both in vitro and in vivo experiments affirm the essential fuction of LDB1 in the proliferation and survival of cell lines derived from T-ALL, with MYB identified as a significant downstream target of LDB1.</p><p><strong>Conclusions: </strong>To sum up, our research establishes the pivotal fuction of LDB1 in the tumorigenesis and progression of T-ALL cell lines. Mechanistic insights reveal that LDB1 cooperates with ERG, ETV6, and IRF1 to modulate the expression of downstream effector genes. Furthermore, LDB1 controls MYB through remote enhancer modulation, providing valuable mechanistic insights into its involvement in the progression of T-ALL.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"283"},"PeriodicalIF":11.4000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462673/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental & Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13046-024-03199-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite significant progress in the prognosis of pediatric T-cell acute lymphoblastic leukemia (T-ALL) in recent decades, a notable portion of children still confronts challenges such as treatment resistance and recurrence, leading to limited options and a poor prognosis. LIM domain-binding protein 1 (LDB1) has been confirmed to exert a crucial role in various physiological and pathological processes. In our research, we aim to elucidate the underlying function and mechanisms of LDB1 within the background of T-ALL.

Methods: Employing short hairpin RNA (shRNA) techniques, we delineated the functional impact of LDB1 in T-ALL cell lines. Through the application of RNA-Seq, CUT&Tag, and immunoprecipitation assays, we scrutinized master transcription factors cooperating with LDB1 and identified downstream targets under LDB1 regulation.

Results: LDB1 emerges as a critical transcription factor co-activator in cell lines derived from T-ALL. It primarily collaborates with master transcription factors (ERG, ETV6, IRF1) to cooperatively regulate the transcription of downstream target genes. Both in vitro and in vivo experiments affirm the essential fuction of LDB1 in the proliferation and survival of cell lines derived from T-ALL, with MYB identified as a significant downstream target of LDB1.

Conclusions: To sum up, our research establishes the pivotal fuction of LDB1 in the tumorigenesis and progression of T-ALL cell lines. Mechanistic insights reveal that LDB1 cooperates with ERG, ETV6, and IRF1 to modulate the expression of downstream effector genes. Furthermore, LDB1 controls MYB through remote enhancer modulation, providing valuable mechanistic insights into its involvement in the progression of T-ALL.

增强子循环蛋白 LDB1 通过与主转录因子合作调节体外 T-ALL 细胞系中 MYB 的表达。
背景:尽管近几十年来小儿T细胞急性淋巴细胞白血病(T-ALL)的预后取得了重大进展,但仍有相当一部分患儿面临耐药和复发等挑战,导致治疗选择有限且预后不佳。LIM结构域结合蛋白1(LDB1)已被证实在各种生理和病理过程中发挥着至关重要的作用。在我们的研究中,我们的目标是在T-ALL的背景下阐明LDB1的潜在功能和机制:方法:利用短发夹 RNA(shRNA)技术,我们研究了 LDB1 在 T-ALL 细胞系中的功能影响。通过应用 RNA-Seq、CUT&Tag 和免疫沉淀实验,我们仔细研究了与 LDB1 合作的主转录因子,并确定了受 LDB1 调控的下游靶标:结果:在T-ALL细胞系中,LDB1是一个关键的转录因子共激活因子。它主要与主转录因子(ERG、ETV6、IRF1)合作,共同调控下游靶基因的转录。体外和体内实验都证实了 LDB1 在 T-ALL 细胞系的增殖和存活过程中起着至关重要的作用,而 MYB 被确定为 LDB1 的一个重要下游靶标:综上所述,我们的研究证实了 LDB1 在 T-ALL 细胞系的肿瘤发生和发展过程中的关键作用。机理揭示了 LDB1 与 ERG、ETV6 和 IRF1 合作调节下游效应基因的表达。此外,LDB1 还通过远程增强子调控来控制 MYB,为其参与 T-ALL 的进展提供了宝贵的机理启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
18.20
自引率
1.80%
发文量
333
审稿时长
1 months
期刊介绍: The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications. We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options. We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us. We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community. By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信